These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36818772)

  • 1. Successful Management of Severe Hyperhaemolysis with Combined Tocilizumab and Rituximab in Non-Transfusion-Dependent Thalassaemia: A Case Report.
    El Afifi AM; Saeed AM; Fekry GH; Mostafa MA; Elmetwally RA; Hamed IM; Hussein AN; Hasanien GM
    Transfus Med Hemother; 2023 Feb; 50(1):66-70. PubMed ID: 36818772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
    Pantelidou D; Pilalas D; Daios S; Polychronopoulos G; Papadopoulou D; Perifanis V; Savopoulos C; Kaiafa G
    J Clin Pharm Ther; 2022 Mar; 47(3):411-414. PubMed ID: 34397109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperhaemolysis caused by anti-HI antibodies in a patient with myelodysplastic syndrome following a first ever red cell transfusion.
    Hinton R; Haji R; Kaczmarski R; Layton M; Danga A
    Transfus Med; 2023 Aug; 33(4):349-351. PubMed ID: 37186414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal Delayed Haemolytic Transfusion Reaction and Hyperhaemolysis Syndrome in a Pregnant Woman with Sickle Cell Anaemia.
    Asnawi AW; Sathar J; Mohamed R; Deraman R; Kumaran S; Hamid SS; Zakaria MZ
    Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):251-3. PubMed ID: 27408406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperhaemolysis syndrome in a patient with myelofibrosis.
    Treleaven JG; Win N
    Hematology; 2004 Apr; 9(2):147-9. PubMed ID: 15203871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed haemolytic transfusion reaction and hyperhaemolysis complicating peri-operative blood transfusion in sickle cell disease.
    McGlennan AP; Grundy EM
    Anaesthesia; 2005 Jun; 60(6):609-12. PubMed ID: 15918834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
    Cullis JO; Win N; Dudley JM; Kaye T
    Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tocilizumab in the treatment of post-transfusion hyperhaemolysis.
    Desai N; Peters J; Davies E; Sharif J
    EJHaem; 2023 Nov; 4(4):1096-1099. PubMed ID: 38024590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory hyperhaemolysis in a patient with beta-thalassaemia major.
    Grainger JD; Makar Y; McManus A; Wynn R
    Transfus Med; 2001 Feb; 11(1):55-7. PubMed ID: 11328573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.
    Madu AJ; Ugwu AO; Efobi C
    Med Princ Pract; 2021; 30(3):236-243. PubMed ID: 33176303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful management of the potentially fatal hyperhaemolysis syndrome of sickle cell anaemia with a regimen including bortezomib and Hemopure.
    Epstein SS; Hadley TJ
    J Clin Pharm Ther; 2019 Oct; 44(5):815-818. PubMed ID: 31237703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage of refractory post-transfusion hyperhaemolysis by targeting hyperinflammation and macrophage activation with tocilizumab.
    Chen F; Booth C; Barroso F; Bennett S; Kaya B; Win N; Telfer P
    Transfus Med; 2022 Oct; 32(5):437-440. PubMed ID: 34046955
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
    BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
    Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
    Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion.
    Wu Y; Ji Y; Dai B; Guo F; Wu Y; He Z; Mo C; Wu S; Hu Y
    Transfus Med; 2021 Feb; 31(1):24-29. PubMed ID: 33331032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
    Sivapalaratnam S; Linpower L; Sirigireddy B; Agapidou A; Jain S; Win N; Tsitsikas DA
    Br J Haematol; 2019 Sep; 186(6):e212-e214. PubMed ID: 31368112
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura: A case report.
    Chaurasiya PS; Khatri A; Gurung S; Karki S; Shahi S; Aryal L
    Ann Med Surg (Lond); 2022 Oct; 82():104789. PubMed ID: 36268380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathological evidence for macrophage activation driving post-transfusion hyperhaemolysis syndrome.
    Win N; Lucas S; Hebballi S; McKernan A; Hamilton R; Robinson I; Chen F
    Br J Haematol; 2019 Aug; 186(3):499-502. PubMed ID: 31020643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cold agglutinin disease -  no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
    Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
    Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.